(Bloomberg) — Alibaba Group Holding Ltd.’s profit surged a better-than-expected 69% after China’s e-commerce leader reined in spending and narrowed losses abroad, taking steps to make up for anemic growth in a Covid-struck home market.

The reaction of the auditing news will support the group continue the upward trend.

$BABA riding this one down, great starting position for the group 💎

Stocks are entering a fresh bull cycle after a painful 2022 performance, supported by the potential of the world's largest economy sidestepping a recession, Leuthold Group chief investment strategist Jim Paulsen, told Bloomberg.

$BABA Alibaba Group Holding (BABA, $80.51) tops fiscal Q2 earnings expectations.

$BABA The current ROCE for $BABA still remains at a highly competitive level, even when compared to the #FAAMG group,as you can see in the second chart below.

1) Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has once again excelled in its mission of supporting the group’s 11.11 Global Shopping Festival, thanks to its high-performance computing and innovative technology.

$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!

$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!

But doesnt change the fact that we have a very safe and effective drug for alz, much better than competitors with more favorable sub group data likely to follow soon.

$AVXL patients and special interest groups will come to Anavex wanting Blarcamesine! !

Sub group analysis for 50 mg dosing is remarkable.

I think certainly the patient groups will be very interested.

Do not forget they met all endpoints for the 2 groups COMBINED!

$AVXL importantly there a so-called superresponders in the blacarmesine treatment group, they improved in cognition score and these are 84% more than observed without that treatment.

Patient advocate groups will push for approval! !

And these posters are not child’s play they’re very detailed - they pack a lot of information onto one poster so a small group of people must have the results.

What a group, a round of applause in order for the guys/gals who helped make this happen.